Pennant Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Pennant Group wird ein Gewinn- und Umsatzwachstum von 26.6% bzw. 13.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 22.6% pro Jahr wachsen soll.

Wichtige Informationen

26.6%

Wachstumsrate der Gewinne

22.6%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.1%
Wachstumsrate der Einnahmen	13.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?

Oct 06

Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)

Sep 14

Investors Could Be Concerned With Pennant Group's (NASDAQ:PNTG) Returns On Capital

Dec 25

Pennant Group (NASDAQ:PNTG) Is Reinvesting At Lower Rates Of Return

Sep 02

Pennant acquires California-based Ardent Hospice and Palliative Care

Aug 16

Pennant Non-GAAP EPS of $0.14 in-line, revenue of $116.3M beats by $4.02M

Aug 08

Pennant Group (NASDAQ:PNTG) Takes On Some Risk With Its Use Of Debt

Jun 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PNTG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	855	38	35	N/A	4
12/31/2025	788	33	29	N/A	4
12/31/2024	679	24	25	N/A	4
6/30/2024	612	19	8	29	N/A
3/31/2024	575	16	16	25	N/A
12/31/2023	545	13	25	33	N/A
9/30/2023	524	13	14	24	N/A
6/30/2023	502	13	9	20	N/A
3/31/2023	486	7	8	22	N/A
12/31/2022	473	7	-5	9	N/A
9/30/2022	460	1	-5	8	N/A
6/30/2022	454	-3	-13	-2	N/A
3/31/2022	448	3	-23	-15	N/A
12/31/2021	440	3	-25	-18	N/A
9/30/2021	436	9	-20	-16	N/A
6/30/2021	422	12	-9	-5	N/A
3/31/2021	405	14	36	41	N/A
12/31/2020	391	16	43	50	N/A
9/30/2020	372	8	41	50	N/A
6/30/2020	362	5	40	49	N/A
3/31/2020	352	4	4	13	N/A
12/31/2019	339	3	3	10	N/A
9/30/2019	324	10	14	19	N/A
6/30/2019	309	13	12	18	N/A
3/31/2019	296	14	15	19	N/A
12/31/2018	286	16	19	23	N/A
12/31/2017	251	10	N/A	17	N/A
12/31/2016	217	8	N/A	16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PNTGDas prognostizierte Gewinnwachstum (26.6% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: PNTGDie Erträge des Unternehmens (26.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: PNTGEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: PNTGDie Einnahmen des Unternehmens (13.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: PNTGDie Einnahmen des Unternehmens (13.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PNTG in 3 Jahren voraussichtlich hoch sein wird

Pennant Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 12% to US$37.50

Price target increased by 9.5% to US$34.50

Price target increased by 12% to US$33.50

The Pennant Group, Inc. Updates Earnings Guidance for the Year 2024

Price target increased by 7.8% to US$27.50

Price target increased by 13% to US$24.75

Recent updates

Price target increased by 12% to US$37.50

The Pennant Group, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Price target increased by 9.5% to US$34.50

Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?

The Pennant Group, Inc. has completed a Follow-on Equity Offering in the amount of $108.5 million.

New minor risk - Shareholder dilution

The Pennant Group, Inc. has completed a Follow-on Equity Offering in the amount of $108.5 million.

The Pennant Group, Inc. has filed a Follow-on Equity Offering.

The Pennant Group, Inc. has filed a Follow-on Equity Offering.

Now 21% undervalued

Price target increased by 12% to US$33.50

Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)

Now 21% undervalued

Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued

The Pennant Group, Inc. Updates Earnings Guidance for the Year 2024

CEO & Director notifies of intention to sell stock

The Pennant Group, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Price target increased by 7.8% to US$27.50

Independent Director exercised options to buy US$1.3m worth of stock.

The Pennant Group, Inc. acquired Nurses On Wheels, Inc.

Now 21% undervalued

Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly

Price target increased by 13% to US$24.75

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

The Pennant Group, Inc. (NasdaqGS : PNTG) acquired South Davis Community Hospital, Inc.

The Pennant Group, Inc. to Report Q1, 2024 Results on May 06, 2024

New minor risk - Shareholder dilution

The Pennant Group, Inc., Annual General Meeting, May 23, 2024

President & COO exercised options to buy US$214k worth of stock.

The Pennant Group, Inc. (NASDAQ:PNTG) Not Flying Under The Radar

Price target increased by 22% to US$19.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

The Pennant Group, Inc. Provides Revenue Guidance for 2024

The Pennant Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Pennant Group (NASDAQ:PNTG) Takes On Some Risk With Its Use Of Debt

Price target increased by 10% to US$16.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

the Pennant Group, Inc. Provides Earnings Guidance for the Year 2023

The Pennant Group, Inc. (NasdaqGS:PNTG) acquired Guardian Hospice of Texas and Guardian Hospice of Oklahoma.

The Pennant Group, Inc. to Report Q3, 2023 Results on Nov 07, 2023

The Pennant Group, Inc. (NasdaqGS:PNTG) acquired Valor HospiceCare.

Price target decreased by 7.1% to US$14.25

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

The Pennant Group, Inc. to Report Q2, 2023 Results on Aug 08, 2023

The Pennant Group, Inc. (NasdaqGS:PNTG) acquired Bluebird Home Health, Bluebird Hospice, and Bluebird Home Care.

Price target decreased by 8.5% to US$15.33

The Pennant Group, Inc. Announces Jennifer Freeman Assume the Role of Senior Vice President of Strategic Partnerships

Investor sentiment deteriorates as stock falls 18%

The Pennant Group, Inc. acquired Assets Of Benefit Health Care.

The Returns On Capital At Pennant Group (NASDAQ:PNTG) Don't Inspire Confidence

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 16%

Independent Chairman recently bought US$67k worth of stock

Investor sentiment improves as stock rises 20%

Is Pennant Group (NASDAQ:PNTG) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

The Pennant Group, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investors Could Be Concerned With Pennant Group's (NASDAQ:PNTG) Returns On Capital

Consensus forecasts updated

The Pennant Group, Inc. (NasdaqGS:PNTG) announces an Equity Buyback for $1 million worth of its shares.

Independent Director recently bought US$203k worth of stock

Consensus forecasts updated

Consensus forecasts updated

The Pennant Group, Inc. Announces Resignation of Derek Bunker,Chief Investment Officer, Executive Vice President and Corporate Secretary, Effective December 31, 2022

Price target decreased to US$15.40

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

The Pennant Group, Inc. Provides Earnings Guidance for the Year 2022